Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 133Stomach Neoplasms 111Colonic Neoplasms 101Pancreatic Neoplasms 81Neoplasm Metastasis 57Esophageal Neoplasms 48Neoplasms 31Adenocarcinoma Of Esophagus 23Adenocarcinoma 21Carcinoma, Hepatocellular 20Carcinoma, Non-Small-Cell Lung 16Biliary Tract Neoplasms 16Gallbladder Neoplasms 15Cholangiocarcinoma 15Gastrointestinal Neoplasms 14Liver Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Unspecified Adult Solid Tumor, Protocol Specific 11Esophageal Squamous Cell Carcinoma 11Bile Duct Neoplasms 10Recurrence 9Peritoneal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Appendiceal Neoplasms 5Advanced Gastric Cancer 5

Interventions

Fluorouracil 2Docetaxel 2thymoglobulin 1temsirolimus 1sargramostim 1pirarubicin 1pembrolizumab 1pazopanib 1fludarabine phosphate 1fludarabine 1cc-486 1X-Rays 1Whole-Body Irradiation 1Trastuzumab 1Tacrolimus 1Surveys and Questionnaires 1Rituximab 1Radiotherapy 1Proctectomy 1Pemetrexed 1Oxaliplatin 1Mycophenolic Acid 1Monatide (IMS 3015) 1Metformin 1Melphalan 1Leucovorin 1Granulocyte-Macrophage Colony-Stimulating Factor 1Epirubicin 1Drug Therapy 1Diphenhydramine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Complete Response × Oxaliplatin × Clear all
NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡